{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T07:04:28Z","timestamp":1784790268029,"version":"3.55.0"},"reference-count":94,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Hepatic malignancies account for a substantial portion of global cancer mortality, with hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (IHC), and metastatic liver disease representing the most common diagnoses. While surgical resection and liver transplantation remain curative options for eligible patients, most patients are diagnosed at stages unsuitable for surgery. This has shifted medical management towards locoregional therapies (LRTs) which are often catheter-directed. Of these interventions, the use of conventional end-hole catheters for therapeutic infusion has been a mainstay of treatment, but this method is constrained by retrograde particle escape and elevated tumoral interstitial fluid pressure. Together, these factors limit drug penetration into the tumor microenvironment. Pressure-enabled drug delivery (PEDD), achieved through balloon-occlusion or microvalve-based catheter platforms, has emerged as a strategy to overcome these limitations. This narrative review synthesizes current evidence regarding PEDD and contextualizes its role within the broader LRT landscape. Preclinical studies and early clinical data illustrate improved drug-delivery characteristics, acceptable safety profiles, and highlight the potential for adaptation to regional immunotherapy regimens. However, while PEDD represents a promising advance in catheter-based hepatic oncologic therapy, prospective randomized comparisons against conventional infusion remain limited, and significant investigation is needed to establish its definitive role in interventional oncology.<\/jats:p>","DOI":"10.3390\/cancers18152367","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T06:11:42Z","timestamp":1784787102000},"page":"2367","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Locoregional Therapy Pressure-Enabled Drug Delivery for Liver Cancers"],"prefix":"10.3390","volume":"18","author":[{"given":"Thomas","family":"Eggleston","sequence":"first","affiliation":[{"name":"Corewell Health Lakeland Hospitals\u2014St. Joseph\u2019s Hospital, St. Joseph, MI 49085, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1300-0309","authenticated-orcid":false,"given":"Fady Bassem","family":"Fayek","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Kowalke","sequence":"additional","affiliation":[{"name":"The Kentucky College of Osteopathic Medicine, Pikeville, KY 41501, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2498-7132","authenticated-orcid":false,"given":"Mina S.","family":"Makary","sequence":"additional","affiliation":[{"name":"Division of Vascular and Interventional Radiology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Garg, T., Shrigiriwar, A., Habibollahi, P., Cristescu, M., Liddell, R.P., Chapiro, J., Inglis, P., Camacho, J.C., and Nezami, N. (2022). Intra-arterial Therapies for the Management of Hepatocellular Carcinoma. Cancers, 14.","DOI":"10.3390\/cancers14143351"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.jvir.2013.03.034","article-title":"Barriers to drug delivery in interventional oncology","volume":"24","author":"Sheth","year":"2013","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Cournoyer, L., Liu, Y., Jaroch, D.B., Hullinger, T.G., Cox, B.F., Katz, S.C., LaPorte, J., Layman, I.B., Ballarin, A., and Ghosh, C.C. (2025). Pressure enabled drug delivery (PEDD) of nelitolimod increased therapeutic delivery, reduced immunosuppression, and improved efficacy in porcine and murine liver tumor models. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1655794"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1055\/s-0028-1085930","article-title":"An overview of embolic agents","volume":"25","author":"Vaidya","year":"2008","journal-title":"Semin. Interv. Radiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"435120","DOI":"10.1155\/2015\/435120","article-title":"Transarterial Embolization for Hepatocellular Carcinoma: A Comparison between Nonspherical PVA and Microspheres","volume":"2015","author":"Scaffaro","year":"2015","journal-title":"BioMed Res. Int."},{"key":"ref_6","first-page":"96","article-title":"Transcatheter embolization therapy in liver cancer: An update of clinical evidences","volume":"27","author":"Ballet","year":"2015","journal-title":"Chin. J. Cancer Res."},{"key":"ref_7","first-page":"E210","article-title":"Embolics review: Current options and agents in the pipeline","volume":"20","author":"Guan","year":"2023","journal-title":"Vasc. Dis. Manag."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Jipa, A.M., and Makary, M.S. (2024). Locoregional Therapies for Hepatobiliary Tumors: Contemporary Strategies and Novel Applications. Cancers, 16.","DOI":"10.3390\/cancers16071271"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2147\/JHC.S103661","article-title":"Transarterial chemoembolization for the treatment of hepatocellular carcinoma: A review","volume":"4","author":"Sacco","year":"2017","journal-title":"J. Hepatocell. Carcinoma"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.hpb.2024.08.011","article-title":"Trans-arterial embolization versus chemoembolization for neuroendocrine liver metastases: A propensity matched analysis","volume":"26","author":"Ruff","year":"2024","journal-title":"HPB"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Crocetti, L., Bozzi, E., Scalise, P., Bargellini, I., Lorenzoni, G., Ghinolfi, D., Campani, D., Balzano, E., De Simone, P., and Cioni, R. (2021). Locoregional Treatments for Bridging and Downstaging HCC to Liver Transplantation. Cancers, 13.","DOI":"10.3390\/cancers13215558"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Fazlollahi, F., Carfora, A.D., King, M., Wrasman, E.S., and Makary, M.S. (2026). The State of the Art in Combination Locoregional and Systemic Treatment Strategies for Hepatocellular Carcinoma: Recent Advancements and Future Horizons. Curr. Oncol., 33.","DOI":"10.3390\/curroncol33030172"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1148\/radiographics.18.3.9599386","article-title":"Complications associated with transcatheter arterial embolization for hepatic tumors","volume":"18","author":"Sakamoto","year":"1998","journal-title":"RadioGraphics"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Makary, M.S., Khandpur, U., Cloyd, J.M., Mumtaz, K., and Dowell, J.D. (2020). Locoregional Therapy Approaches for Hepatocellular Carcinoma: Recent Advances and Management Strategies. Cancers, 12.","DOI":"10.3390\/cancers12071914"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s12029-025-01280-2","article-title":"Locoregional Therapies for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus","volume":"56","author":"Singh","year":"2025","journal-title":"J. Gastrointest. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1111\/hpb.12487","article-title":"Post-embolization syndrome as an early predictor of overall survival after transarterial chemoembolization for hepatocellular carcinoma","volume":"17","author":"Mason","year":"2015","journal-title":"HPB"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"10960","DOI":"10.3748\/wjg.v20.i31.10960","article-title":"Chemotherapy for transarterial chemoembolization in patients with unresectable hepatocellular carcinoma","volume":"20","author":"Wu","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Lanza, C., Ascenti, V., Amato, G.V., Pellegrino, G., Triggiani, S., Tintori, J., Intrieri, C., Angileri, S.A., Biondetti, P., and Carriero, S. (2025). All You Need to Know About TACE: A Comprehensive Review of Indications, Techniques, Efficacy, Limits, and Technical Advancement. J. Clin. Med., 14.","DOI":"10.3390\/jcm14020314"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Makary, M.S., Alexander, J., Regalado, L.E., Jalil, S., and Mumtaz, K. (2024). Clinical outcomes of DEB-TACE in locally advanced hepatocellular carcinoma: A 5-year real world experience. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0309693"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jhep.2006.10.020","article-title":"Chemoembolization of hepatocellular carcinoma with drug eluting beads: Efficacy and doxorubicin pharmacokinetics","volume":"46","author":"Varela","year":"2007","journal-title":"J. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4132","DOI":"10.1007\/s00330-024-11272-8","article-title":"Degradable starch microspheres transarterial chemoembolization (DSM-TACE) in patients with unresectable hepatocellular carcinoma: Results from the Prospective Multicenter Observational HepaStar Trial","volume":"35","author":"Collettini","year":"2025","journal-title":"Eur. Radiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"103905","DOI":"10.1016\/j.jddst.2022.103905","article-title":"Current status of transarterial chemoembolization (TACE) agents in hepatocellular carcinoma treatment","volume":"77","author":"Goodarzi","year":"2022","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"72613","DOI":"10.18632\/oncotarget.19997","article-title":"Transarterial chemoembolization (TACE) with degradable starch microspheres (DSM) in hepatocellular carcinoma (HCC): Multi-center results on safety and efficacy","volume":"8","author":"Schicho","year":"2017","journal-title":"Oncotarget"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/j.1572-0241.2007.01712.x","article-title":"Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): The role of angiogenesis and invasiveness","volume":"103","author":"Sergio","year":"2008","journal-title":"Am. J. Gastroenterol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.20517\/2394-5079.2022.66","article-title":"Chemoembolization with Degradable Starch Microspheres (DSM-TACE): Expanding indications in HCC multidisciplinary tumor board","volume":"9","author":"Rozzanigo","year":"2023","journal-title":"Hepatoma Res."},{"key":"ref_26","first-page":"101018","article-title":"A comparative study of DEB-TACE alone and DEB-TACE combined with targeted therapy and immunotherapy in the treatment of intermediate-advanced hepatocellular carcinoma","volume":"45","author":"Wu","year":"2025","journal-title":"Cancer Treat. Res. Commun."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"109419","DOI":"10.5306\/wjco.v16.i8.109419","article-title":"Combination therapy reduces transarterial chemoembolization resistance in advanced hepatocellular carcinoma","volume":"16","author":"Jiao","year":"2025","journal-title":"World J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Lalenis, C., Posa, A., Lancellotta, V., Lippi, M., Marazzi, F., Barbieri, P., Cornacchione, P., Fischer, M.J., Tagliaferri, L., and Iezzi, R. (2025). TACE Versus TARE in the Treatment of Liver-Metastatic Breast Cancer: A Systematic Review. Tomography, 11.","DOI":"10.3390\/tomography11070081"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.1245\/s10434-024-15187-y","article-title":"Outcomes of Hepatic Artery-Based Therapies and Systemic Multiagent Chemotherapy in Unresectable Colorectal Liver Metastases: A Systematic Review and Meta-analysis","volume":"31","author":"Sugumar","year":"2024","journal-title":"Ann. Surg. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00432-025-06274-y","article-title":"Comparison of TACE alone versus TACE combined with synchronous ablation for neuroendocrine neoplasms with liver metastases","volume":"151","author":"Sun","year":"2025","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Remiszewski, P., Topolewski, P., \u0141aski, D., and Drobi\u0144ska, A. (2024). Outcomes of Bridging Therapy in Liver Transplantation for Hepatocellular Carcinoma. J. Clin. Med., 13.","DOI":"10.3390\/jcm13226633"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"570962","DOI":"10.2147\/JHC.S570962","article-title":"Development of a Nomogram Model to Predict Post-Transplant Tumor Recurrence in Patients with Hepatocellular Carcinoma Beyond the Milan Criteria Undergoing TACE Bridging Therapy","volume":"13","author":"Wang","year":"2026","journal-title":"J. Hepatocell. Carcinoma"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.cld.2020.08.002","article-title":"Expanding the limits of liver transplantation for hepatocellular carcinoma: Is there a limit?","volume":"25","author":"Kwong","year":"2021","journal-title":"Clin. Liver Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.3390\/curroncol31040154","article-title":"Liver-Directed Locoregional Therapies for Neuroendocrine Liver Metastases: Recent Advances and Management","volume":"31","author":"Criss","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Kim, J.H., Kim, J.H., Yoon, H.K., Ko, G.Y., Shin, J.H., Gwon, D.I., Ko, H.K., Chu, H.H., Kim, S.H., and Kim, G.H. (2023). Transarterial chemoembolization for advanced hepatocellular carcinoma without macrovascular invasion or extrahepatic metastasis: Analysis of factors prognostic of clinical outcomes. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1072922"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.semradonc.2011.05.004","article-title":"Radioembolization for Primary and Metastatic Liver Cancer","volume":"21","author":"Memon","year":"2011","journal-title":"Semin. Radiat. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3748\/wjg.v29.i3.413","article-title":"Salvage locoregional therapies for recurrent hepatocellular carcinoma","volume":"29","author":"Criss","year":"2023","journal-title":"World J. Gastroenterol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.jvir.2023.03.011","article-title":"Evolution of Personalized Dosimetry for Radioembolization of Hepatocellular Carcinoma","volume":"34","author":"Knight","year":"2023","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","article-title":"Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): A randomised, multicentre, open-label phase 2 trial","volume":"6","author":"Garin","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/hep.31819","article-title":"Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study","volume":"74","author":"Salem","year":"2021","journal-title":"Hepatology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s00270-021-02800-w","article-title":"Transarterial Chemoembolization and Radioembolization for Unresectable Intrahepatic Cholangiocarcinoma\u2014A Systemic Review and Meta-Analysis","volume":"44","author":"Mosconi","year":"2021","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"O\u2019Donnell, C.D.J., Majeed, U., Rutenberg, M.S., Croome, K.P., Poruk, K.E., Toskich, B., and Jin, Z. (2025). Advancements in Locoregional Therapies for Unresectable Intrahepatic Cholangiocarcinoma. Curr. Oncol., 32.","DOI":"10.3390\/curroncol32020082"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Zane, K.E., and Makary, M.S. (2021). Locoregional Therapies for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. Cancers, 13.","DOI":"10.3390\/cancers13215430"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1055\/s-0041-1735530","article-title":"Radiation Lobectomy: An Overview of Concept and Applications, Technical Considerations, Outcomes","volume":"38","author":"Entezari","year":"2021","journal-title":"Semin. Interv. Radiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"738","DOI":"10.4254\/wjh.v7.i5.738","article-title":"Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: Role and perspectives","volume":"7","author":"Mosconi","year":"2015","journal-title":"World J. Hepatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"20220470","DOI":"10.1259\/bjr.20220470","article-title":"Lung shunt fraction quantification methods in radioembolization: What you need to know","volume":"95","author":"Torkian","year":"2022","journal-title":"Br. J. Radiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1097\/PAS.0000000000001901","article-title":"Gastrointestinal Tract Injury by Yttrium-90 Appears Largely Restricted to Resin Microspheres But Can Occur Years After Embolization","volume":"46","author":"Feely","year":"2022","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1158\/0008-5472.CAN-13-3696","article-title":"Releasing pressure in tumors: What do we know so far and where do we go from here? A review","volume":"74","author":"Ariffin","year":"2014","journal-title":"Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"18632","DOI":"10.1073\/pnas.1318415110","article-title":"Combining two strategies to improve perfusion and drug delivery in solid tumors","volume":"110","author":"Stylianopoulos","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12967-025-06124-y","article-title":"High interstitial fluid pressure enhances USP1-dependent KIF11 protein stability to promote hepatocellular carcinoma progression","volume":"23","author":"Wu","year":"2025","journal-title":"J. Transl. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1586\/17434440.2016.1164594","article-title":"Evaluation of Surefire\u2019s precision direct-to-tumor embolization device to augment therapeutic response to intra-arterial, liver-directed therapies for patients with primary and secondary liver cancers","volume":"13","author":"Kim","year":"2016","journal-title":"Expert Rev. Med. Devices"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13046-015-0188-8","article-title":"Innovation in catheter design for intra-arterial liver cancer treatments results in favorable particle-fluid dynamics","volume":"34","author":"Lam","year":"2015","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1007\/s00270-012-0476-z","article-title":"Dense accumulation of lipiodol emulsion in hepatocellular carcinoma nodule during selective balloon-occluded transarterial chemoembolization: Measurement of balloon-occluded arterial stump pressure","volume":"36","author":"Irie","year":"2013","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s11604-019-00836-0","article-title":"Change in hepatic hemodynamics assessed by hepatic arterial blood pressure and computed tomography during hepatic angiography with the double balloon technique","volume":"37","author":"Inoue","year":"2019","journal-title":"Jpn. J. Radiol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/hepr.12403","article-title":"Safety and efficacy of balloon-occluded transcatheter arterial chemoembolization using miriplatin for hepatocellular carcinoma","volume":"45","author":"Arai","year":"2015","journal-title":"Hepatol. Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"E60","DOI":"10.1111\/hepr.12527","article-title":"Efficacy of a microballoon catheter in transarterial chemoembolization of hepatocellular carcinoma using miriplatin, a lipophilic anticancer drug: Short-term results","volume":"46","author":"Ogawa","year":"2016","journal-title":"Hepatol. Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/hepr.12564","article-title":"Selective balloon-occluded transarterial chemoembolization for patients with one or two hepatocellular carcinoma nodules: Retrospective comparison with conventional super-selective TACE","volume":"46","author":"Irie","year":"2016","journal-title":"Hepatol. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s00270-021-03035-5","article-title":"In vivo comparison of micro-balloon interventions (MBI) advantage: A retrospective cohort study of DEB-TACE versus b-TACE and of SIRT versus b-SIRT","volume":"45","author":"Lucatelli","year":"2022","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1007\/s00270-021-02805-5","article-title":"Retrospective European multicentric evaluation of selective transarterial chemoembolisation with and without balloon-occlusion in patients with hepatocellular carcinoma: A propensity score matched analysis","volume":"44","author":"Golfieri","year":"2021","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Lucatelli, P., De Rubeis, G., Rocco, B., Basilico, F., Cannavale, A., Abbatecola, A., Nardis, P.G., Corona, M., Brozzetti, S., and Catalano, C. (2021). Balloon occluded TACE (B-TACE) vs. DEM-TACE for HCC: A single center retrospective case control study. BMC Gastroenterol., 21.","DOI":"10.1186\/s12876-021-01631-w"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"9289321","DOI":"10.1155\/2020\/9289321","article-title":"Balloon-Occluded Trans-Arterial Chemo-Embolization Technique with Repeated Alternate Infusion of Cisplatin Solution and Sparse Gelatin Slurry (RAIB-TACE) for Large Hepatocellular Carcinoma Nodules More than 7 cm in Diameter","volume":"2020","author":"Irie","year":"2020","journal-title":"Biomed. Res. Int."},{"key":"ref_63","unstructured":"(2018). Sniper Balloon Occlusion Microcatheter: Product Information, Embolx, Inc."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"108826","DOI":"10.1016\/j.jvir.2026.108826","article-title":"Lipiodol-based balloon-occluded transcatheter arterial chemoembolization can be a curative treatment option for hepatocellular carcinoma","volume":"37","author":"Gwon","year":"2026","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1007\/s00270-012-0538-2","article-title":"Downstream hepatic arterial blood pressure changes caused by deployment of the Surefire antireflux expandable tip","volume":"36","author":"Rose","year":"2013","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jvir.2016.08.007","article-title":"Quantification of blood pressure changes in the vascular compartment when using an anti-reflux catheter during chemoembolization versus radioembolization: A retrospective case series","volume":"28","author":"Rose","year":"2017","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.jvir.2024.06.030","article-title":"Intra-arterial pressure-enabled drug delivery significantly increases penetration of glass microspheres in a porcine liver tumor model","volume":"35","author":"Jaroch","year":"2024","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/scientificamerican0794-58","article-title":"Barriers to drug delivery in solid tumors","volume":"271","author":"Jain","year":"1994","journal-title":"Sci. Am."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.surg.2020.04.059","article-title":"Pressure-enabled delivery of gemcitabine in an orthotopic pancreatic cancer mouse model","volume":"168","author":"Vicente","year":"2020","journal-title":"Surgery"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jvir.2024.11.014","article-title":"Pressure-enabled drug delivery significantly increases intra-arterial delivery of embolic microspheres to liver tumors in a porcine model","volume":"36","author":"Jaroch","year":"2025","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/s00270-018-2150-6","article-title":"End-hole versus microvalve infusion catheters in patients undergoing drug-eluting microspheres-TACE for solitary hepatocellular carcinoma tumors: A retrospective analysis","volume":"42","author":"Titano","year":"2019","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jvir.2015.01.029","article-title":"The impact of an antireflux catheter on target volume particulate distribution in liver-directed embolotherapy: A pilot study","volume":"26","author":"Pasciak","year":"2015","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Kim, A.Y., Frantz, S., Krishnan, P., DeMulder, D., Caridi, T., Lynskey, G.E., and Spies, J.B. (2017). Short-term imaging response after drug-eluting embolic trans-arterial chemoembolization delivered with the Surefire Infusion System for the treatment of hepatocellular carcinoma. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0183861"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/j.jvir.2014.08.007","article-title":"Prospective, randomized study of coil embolization versus Surefire Infusion System during yttrium-90 radioembolization with resin microspheres","volume":"25","author":"Fischman","year":"2014","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00270-013-0674-3","article-title":"Posttreatment PET-CT-confirmed intrahepatic radioembolization performed without coil embolization, by using the antireflux Surefire Infusion System","volume":"37","author":"Prince","year":"2014","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jvir.2012.12.018","article-title":"Quantification and reduction of reflux during embolotherapy using an antireflux catheter and tantalum microspheres: Ex vivo analysis","volume":"24","author":"Arepally","year":"2013","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.radcr.2022.12.045","article-title":"Large hepatic biloma after bland hepatic arterial embolization using antireflux catheter","volume":"18","author":"Pham","year":"2023","journal-title":"Radiol. Case Rep."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"686","DOI":"10.2214\/AJR.18.19975","article-title":"The Beauty and Bane of Pressure-Directed Embolotherapy: Hemodynamic Principles and Preliminary Clinical Evidence","volume":"212","author":"Rose","year":"2019","journal-title":"Am. J. Roentgenol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e250144","DOI":"10.57264\/cer-2025-0144","article-title":"Clinical outcomes of pressure-enabled drug delivery for trans-arterial chemoembolization and radioembolization","volume":"15","author":"Gupta","year":"2026","journal-title":"J. Comp. Eff. Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1080\/03007995.2024.2322057","article-title":"Real-world evidence of Pressure-Enabled Drug Delivery for trans-arterial chemoembolization and radioembolization among patients with hepatocellular carcinoma and liver metastases","volume":"40","author":"Cook","year":"2024","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00270-014-0941-y","article-title":"Yttrium-90 resin microsphere radioembolization using an antireflux catheter: An alternative to traditional coil embolization for nontarget protection","volume":"38","author":"Morshedi","year":"2015","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/cgt.2016.19","article-title":"Tumor-associated GM-CSF overexpression induces immunoinhibitory molecules via STAT3 in myeloid-suppressor cells infiltrating liver metastases","volume":"23","author":"Thorn","year":"2016","journal-title":"Cancer Gene Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s00262-015-1692-6","article-title":"Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T","volume":"64","author":"Burga","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1038\/s41417-022-00484-z","article-title":"Regional infusion of a class C TLR9 agonist enhances liver tumor microenvironment reprogramming and MDSC reduction to improve responsiveness to systemic checkpoint inhibition","volume":"29","author":"Ghosh","year":"2022","journal-title":"Cancer Gene Ther."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/s41420-021-00621-x","article-title":"Proteomic signatures of myeloid derived suppressor cells from liver and lung metastases reveal functional divergence and potential therapeutic targets","volume":"7","author":"DaSilva","year":"2021","journal-title":"Cell Death Discov."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1158\/1078-0432.CCR-14-1421","article-title":"Phase I Hepatic Immunotherapy for Metastases study of intra-arterial chimeric antigen receptor-modified T-cell therapy for CEA+ liver metastases","volume":"21","author":"Katz","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41417-019-0104-z","article-title":"HITM-SIR: Phase Ib trial of intra-arterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA+ liver metastases","volume":"27","author":"Katz","year":"2020","journal-title":"Cancer Gene Ther."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e001097","DOI":"10.1136\/jitc-2020-001097","article-title":"HITM-SURE: Hepatic immunotherapy for metastases phase Ib anti-CEA CAR-T study utilizing pressure enabled drug delivery","volume":"8","author":"Katz","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.surg.2023.05.011","article-title":"Pressure-Enabled Drug Delivery (PEDD) of a class C TLR9 agonist in combination with checkpoint inhibitor therapy in a murine pancreatic cancer model","volume":"174","author":"Capacio","year":"2023","journal-title":"Surgery"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e008837","DOI":"10.1136\/jitc-2024-008837","article-title":"Subcutaneous checkpoint inhibition is equivalent to systemic delivery when combined with nelitolimod delivered via pressure-enabled drug delivery for depletion of intrahepatic myeloid-derived suppressor cells and control of liver metastases","volume":"12","author":"Ghosh","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1136\/gutjnl-2021-325808","article-title":"Blockade of interleukin 10 potentiates antitumour immune function in human colorectal cancer liver metastases","volume":"72","author":"Sullivan","year":"2022","journal-title":"Gut"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1007\/s00259-020-05079-0","article-title":"Use of an anti-reflux catheter to improve tumor targeting for holmium-166 radioembolization: A prospective, within-patient randomized study","volume":"48","author":"Bastiaannet","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_93","first-page":"44","article-title":"Pressure modification during hepatic tumor embolization: Principles, mechanism of action, and current evidence","volume":"3","author":"Berman","year":"2026","journal-title":"CVIR Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Chai, L.F., Hardaway, J.C., Heatherton, K.R., O\u2019Connell, K.P., Lopes, M.C., Rabinowitz, B.A., Ghosh, C.C., Guha, P., Jaroch, D., and Cox, B.F. (2021). Regional delivery of anti-PD-1 agent for colorectal liver metastases improves therapeutic index and anti-tumor activity. Vaccines, 9.","DOI":"10.3390\/vaccines9080807"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/15\/2367\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T06:16:32Z","timestamp":1784787392000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/15\/2367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":94,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["cancers18152367"],"URL":"https:\/\/doi.org\/10.3390\/cancers18152367","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]}}}